RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.